Login to Your Account



Oxford BioMedica Gets Partner For LentiVector Technology

By Nuala Moran


Wednesday, October 26, 2005
LONDON - Oxford BioMedica plc made significant progress with its gene therapy portfolio, agreeing to a comprehensive deal for the commercialization of its LentiVector technology for use in research, and announcing it has achieved the industry's Holy Grail of generating cytotoxic T-cell responses with the cancer immunotherapeutic TroVax. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription